Bolinder J, Tydén G
Baillieres Clin Gastroenterol. 1989 Oct;3(4):825-33. doi: 10.1016/0950-3528(89)90035-3.
For more than 20 years pancreas transplantation has been advocated as a therapeutic modality in patients with insulin-dependent diabetes mellitus. When successful, this procedure is the only method for attaining long-term normoglycaemia in diabetic recipients. However, because of the potential morbidity and mortality, pancreas transplantation should be restricted to diabetic patients in whom the complications of the diabetic state are more serious than those of surgery and chronic immunosuppression. Currently three recipient categories have been identified in which pancreas transplantation would seem justifiable. The first includes diabetic patients with end-stage nephropathy who are already obligated to life-long immunosuppressive therapy because of the kidney replacement. In this recipient category the main benefit of receiving a pancreas transplant in addition to a kidney is that the quality of life is markedly improved. In addition, it seems that a functioning pancreas transplant prevents the recurrence of diabetic nephropathy in the simultaneously transplanted kidney. Since the success rate with combined pancreas-kidney transplantations is approaching that of renal transplantation alone, there is little controversy about performing the combined procedure in diabetic uraemic patients. However, if the main objective of pancreas transplantation, namely to prevent the late diabetic microvascular complications, were to be fulfilled this intervention would have to be performed earlier in the course of the disease. Therefore, single pancreatic transplantations have recently been conducted in diabetic patients with early signs of clinical nephropathy which, currently, is the most powerful predictor of susceptibility to detrimental diabetic complications. Preliminary findings indicate that, in this second recipient category, single pancreatic transplantation and subsequent euglycaemia may prevent the progression of diabetic neuropathy and nephropathy; with regard to diabetic retinopathy the results remain obscure.(ABSTRACT TRUNCATED AT 250 WORDS)
20多年来,胰腺移植一直被提倡作为胰岛素依赖型糖尿病患者的一种治疗方式。该手术成功时,是使糖尿病受者获得长期正常血糖水平的唯一方法。然而,由于存在潜在的发病率和死亡率,胰腺移植应仅限于糖尿病状态的并发症比手术及慢性免疫抑制并发症更严重的患者。目前已确定了三类似乎适合进行胰腺移植的受者。第一类包括患有终末期肾病的糖尿病患者,由于肾脏替代治疗,他们已经必须接受终身免疫抑制治疗。在这类受者中,除了肾脏移植外再接受胰腺移植的主要益处是生活质量明显提高。此外,似乎一个功能正常的胰腺移植可防止同时移植的肾脏中糖尿病肾病的复发。由于胰肾联合移植的成功率已接近单纯肾移植的成功率,因此对于糖尿病尿毒症患者进行联合手术几乎没有争议。然而,如果胰腺移植的主要目标,即预防糖尿病晚期微血管并发症得以实现,那么这种干预必须在疾病进程中更早进行。因此,最近已对有临床肾病早期迹象的糖尿病患者进行了单纯胰腺移植,目前,临床肾病是糖尿病易发生有害并发症的最有力预测指标。初步研究结果表明,在这第二类受者中,单纯胰腺移植及随后的血糖正常可能会阻止糖尿病神经病变和肾病的进展;关于糖尿病视网膜病变,结果仍不明确。(摘要截选至250词)